Therapeutic Uses
Anti-Diabetic
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
7-(2-Butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-8-[(3R)-3-piperidinylamino]-1H-purine-2,6-dione
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Linagliptin Impurity E is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Linagliptin Impurity E usage and description
Linagliptin is an orally administered medication used to treat type 2 diabetes. It works by inhibiting an enzyme in the body called dipeptidyl peptidase-4 (DPP-4), which leads to increased insulin secretion and decreased glucose production in the liver. However, impurities can occasionally be present in pharmaceutical products, which can have negative effects on the safety and efficacy of the medication. One such impurity of linagliptin is impurity E.
Impurity E is a chemical compound that can be present in small amounts in linagliptin tablets. It is a degradation product of the linagliptin molecule that can form during the manufacturing process or storage of the medication. While impurity E is not believed to be harmful at low levels, higher levels could potentially impact the safety and efficacy of the medication.
Thus, it is important to monitor and control the levels of impurity E in linagliptin tablets. This is typically done through rigorous quality control measures during the manufacturing process and regular testing of the final product. Additionally, the chemical structure and properties of impurity E are studied to better understand its potential effects on the body and to develop methods for its detection and removal from the medication.
In summary, while impurity E is a potential concern in linagliptin tablets, it is typically closely monitored and controlled to ensure the safety and efficacy of the medication for individuals with type 2 diabetes.
